A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

NCT06162299 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Business strategy

Conditions

Chronic Hepatitis B

Interventions

BIOLOGICAL: YS-HBV-002

Sponsor

Yisheng Biopharma (Singapore) Pte. Ltd.